213 related articles for article (PubMed ID: 35590044)
1. COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.
De Vincentis S; Domenici D; Ansaloni A; Boselli G; D'Angelo G; Russo A; Taliani E; Rochira V; Simoni M; Madeo B
J Endocrinol Invest; 2022 Oct; 45(10):1887-1897. PubMed ID: 35590044
[TBL] [Abstract][Full Text] [Related]
2. Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia.
Chandran M; Hao Y; Kwee AK; Cheen MHH; Chin YA; Ng VYT
Osteoporos Int; 2022 Jan; 33(1):251-261. PubMed ID: 34417842
[TBL] [Abstract][Full Text] [Related]
3. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia.
Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM
Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
5. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
7. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
Kang MY; Besley J; Sun T; Paul S
N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
[TBL] [Abstract][Full Text] [Related]
9. How the COVID-19 pandemic affected bone health: a retrospective, longitudinal study on denosumab persistence from the epicentre of European spreading.
Varenna M; Orsini F; Di Taranto R; Zucchi F; Manara M; Caporali R; Crotti C
Arch Osteoporos; 2023 Jul; 18(1):95. PubMed ID: 37438617
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Hip Fractures in France During the First COVID-19 Lockdown in Spring 2020.
Paccou J; Lenne X; Ficheur G; Theis D; Cortet B; Bruandet A
JAMA Netw Open; 2021 Nov; 4(11):e2134972. PubMed ID: 34787657
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
12. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
13. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
[TBL] [Abstract][Full Text] [Related]
14. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
15. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
[TBL] [Abstract][Full Text] [Related]
16. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
[TBL] [Abstract][Full Text] [Related]
17. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
19. Has the COVID lockdown altered the incidence and management of fragility fractures in older adults? Case-control study at a French University Hospital.
Runtz A; Sleiman L; Dabert A; Obert L; Garbuio P; Pluvy I; Loisel F
Orthop Traumatol Surg Res; 2023 Feb; 109(1):103419. PubMed ID: 36167250
[TBL] [Abstract][Full Text] [Related]
20. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
